Literature DB >> 24972536

Spasmodic dysphonia: let's look at that again.

Thomas Murry1.   

Abstract

G. Paul Moore influenced the study of spasmodic dysphonia (SD) with his 1960 publication that examined the neurological, medical, and vocal fold behavior in a group of patients with adductor spasmodic dysphonia (ADSD). This review of advances in the diagnosis and treatment of SD follows a time line of research that can be traced in part to the early work of Moore et al. This article reviews the research in ADSD over the past 50 plus years. The capstone events that brought SD to its present day level of management by laryngologists and speech-language pathologists are highlighted. A look to the future to understand more of the disorder is offered for this debilitating disorder.
Copyright © 2014 The Voice Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adductor spasmodic dysphonia; Botulinum toxin; G. Paul Moore

Mesh:

Substances:

Year:  2014        PMID: 24972536     DOI: 10.1016/j.jvoice.2014.03.007

Source DB:  PubMed          Journal:  J Voice        ISSN: 0892-1997            Impact factor:   2.009


  5 in total

Review 1.  Hoarseness-causes and treatments.

Authors:  Rudolf Reiter; Thomas Karl Hoffmann; Anja Pickhard; Sibylle Brosch
Journal:  Dtsch Arztebl Int       Date:  2015-05-08       Impact factor: 5.594

2.  The extrinsic risk and its association with neural alterations in spasmodic dysphonia.

Authors:  Laura de Lima Xavier; Kristina Simonyan
Journal:  Parkinsonism Relat Disord       Date:  2019-05-24       Impact factor: 4.891

3.  Acoustic Model of Perceived Overall Severity of Dysphonia in Adductor-Type Laryngeal Dystonia.

Authors:  Daniel P Buckley; Manuel Diaz Cadiz; Tanya L Eadie; Cara E Stepp
Journal:  J Speech Lang Hear Res       Date:  2020-07-16       Impact factor: 2.297

4.  Botulinum toxin injection into the intrinsic laryngeal muscles to treat spasmodic dysphonia: A multicenter, placebo-controlled, randomized, double-blinded, parallel-group comparison/open-label clinical trial.

Authors:  Masamitsu Hyodo; Asuka Nagao; Kento Asano; Masahiko Sakaguchi; Kenji Mizoguchi; Koichi Omori; Yasuhiro Tada; Hiromitsu Hatakeyama; Nobuhiko Oridate; Kensei Naito; Yoshihiro Iwata; Hirotaka Shinomiya; Hirotaka Hara; Tetsuji Sanuki; Eiji Yumoto
Journal:  Eur J Neurol       Date:  2021-01-23       Impact factor: 6.089

5.  Anxiety and depression in spasmodic dysphonia patients.

Authors:  Amanda Hu; Al Hillel; Wei Zhao; Tanya Meyer
Journal:  World J Otorhinolaryngol Head Neck Surg       Date:  2018-06-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.